Objective: BRCA1/2 mutation carriers have greatly elevated lifetime risks of breast, ovarian, and fallopian tube cancers. Bilateral prophylactic salpingo-oophorectomy is recommended to prevent cancer in these women. As it is often performed before natural menopause, it may be accompanied by menopausal symptoms, impaired quality of life, and increased cardiovascular risk.
B RCA1 and BRCA2 are oncosuppressor genes that play an important role in cellular functions such as DNA damage repair. 1 The estimated frequency of BRCA mutation in the US population is 1 in 400. 2 Interestingly, in a clinical study examining ethnicity-specific BRCA1/2 mutation rates, Nanda et al 3 reported a lower frequency of deleterious mutations (27.9% vs 46.2%) in high-risk African-American families compared with the white population.
Women with a germline mutation in BRCA1 or BRCA2 genes have higher lifetime risks of ovarian (15%-56%) and breast (45%-80%) cancers 4,5 than the general population (ovarian cancer, 1.4%; breast cancer, 12%). 6 Approximately 84% of hereditary breast cancers and more than 90% of hereditary ovarian cancers are caused by mutations in BRCA1 or BRCA2 genes. 7 However, some pieces of evidence demonstrate that BRCA1 mutation carriers demonstrate a risk of developing breast/ ovarian cancers differently from BRCA2 mutation carriers (45%-60% and 11%-35% for BRCA1 and BRCA2, respectively). 8 In detail, among women with BRCA1 mutations, the risk of ovarian cancer starts to increase in the late 30s, with 2% to 3% of them developing gynecologic cancer by the age of 40 years. 5, 9 Conversely, among women with BRCA2 mutations, the risk of gynecologic cancer is only 2% to 3% by the age of 50 years. 5, 9 Regarding breast cancer, the lifetime risk of developing the disease is similar for both BRCA1 and BRCA2 mutation carriers and increases with aging: from 20% in the 40s to 37% by the age of 50 years, rising up to 55% for women in their 60s and above 70% for those older than 70 years. 4 Nevertheless, there is a substantial difference in the phenotypes of BRCA-associated breast cancers. In fact, only 10% to 24% of BRCA1-associated breast cancers are estrogen receptorYpositive, whereas 65% to 79% of BRCA2-associated breast cancers are positive for this receptor. 10, 11 
RISK-REDUCING SALPINGO-OOPHORECTOMY: WHY?
The recommendation for risk-reducing salpingo-oophorectomy (RRSO) among women carrying BRCA mutations is based on the assumption that an equivalent reduction in cancer mortality cannot be achieved with ovarian cancer screening or chemoprevention. 12<14 Conversely, several articles and metaanalyses 15<18 have broadly demonstrated that bilateral prophylactic salpingo-oophorectomy significantly reduces breast cancer risk by approximately 53% to 68% and ovarian cancer risk by 85% to 95%. Furthermore, occult (clinically undetected) cancers have also been found at the time of prophylactic surgical operation in 2% to 18% of women undergoing preventive surgical operation. 19, 20 More recently, considering the substantial difference in the phenotypes of BRCA-associated breast and ovarian cancers, several researches have tried to reach particular estimates for risk reduction in BRCA1 and BRCA2 mutation carriers, separately. RRSO has been proposed to be associated with a significant reduction in BRCA1-associated gynecologic cancer risk and BRCA2-associated breast cancer risk; on the other hand, protection against BRCA1-associated breast cancer and BRCA2-associated gynecologic cancer, even if present, is not statistically significant. 19, 21 However, these observations have been only partially confirmed by Rebbeck et al, 22 who found a statistically significant reduction in breast cancer risk after RRSO for both BRCA1 and BRCA2 mutation carriers. 22 Because of these controversial data, future studies on risk reduction in BRCA mutation carriers are needed to better stratify and assess the risk for each specific mutated gene.
RRSO: WHEN?
The decision to perform RRSO should be made after considering many factors such as desired fertility, childbearing age, and the timing of breast and gynecologic cancer risk. As mentioned earlier, the risk of ovarian cancer in BRCA1mutated women begins to increase in their late 30s, with 2% to 3% of BRCA1 mutation carriers developing gynecologic cancer by the age of 40 years 18 ; therefore, in this setting, RRSO could be a reasonable option by the late 30s to early 40s. For women with BRCA2 mutations, who have a 2% to 3% increased risk of gynecologic cancer by the age of 50 years, 18 RRSO could be delayed until menopause; however, 26% to 34% of these women are thought to develop breast cancer by the age of 50 years, 5, 13, 23 and deferral of RRSO could cause a loss of substantial breast cancer risk protection. 24 Therefore, according to the American College of Obstetrics and Gynecology 25 bulletin of 2008, bilateral salpingooophorectomy should be performed in women with BRCA1 and BRCA2 mutations after the completion of childbearing age (level B). 25 In general, experts currently recommend RRSO in BRCA1/2 mutation carriers at the completion of childbearing age (between 35 and 40 y) or earlier in carriers with a familial history of early-onset cancer. 26 RRSO: SHOULD CONCOMITANT HYSTERECTOMY BE CONSIDERED? Removal of the uterus at the time of salpingo-oophorectomy remains controversial. Indeed, even if the fallopian tubes are carefully ligated at the uterine origin, a small interstitial portion of the tube is left in the uterine fundus and is exposed to a theoretical risk of malignant transformation. 17, 18 Nevertheless, this has never been reported to occur after RRSO in BRCA mutation carriers 18 ; additionally, a clinicopathological study revealed that 92% of 105 tubal carcinomas developed in the distal or medial portion of the tube, 27 limiting the risk of malignant changes. However, hysterectomy can be considered for other reasonsVsuch as reduction of endometrial cancer risk associated with tamoxifen therapy for a previous breast cancer 28 or elimination of a low risk for developing uterine serous papillary carcinoma 29<31 Vand because this less conservative approach may influence the use of hormone therapy (HT) in gene mutation carriers. In fact, given the results of the Women's Health Initiative (WHI) randomized trial, which suggest that estrogen therapy (ET) alone does not adversely modify breast cancer risk, a valid rationale for performing hysterectomy with RRSO would be to permit ET, when desired, avoiding progestins. 25 A bulletin of the American College of Obstetrics and Gynecology 25 states that a clinician may perform concomitant hysterectomy for the following reasons: (1) completely excise the fallopian tubes because of a theoretical risk of fallopian tube cancer; (2) reduce the risk of endometrial pathology in women on tamoxifen therapy; and (3) simplify HT so that estrogen-only therapy may be considered.
IMPLICATIONS AFTER RRSO
Approximately 60% of women with a BRCA1 or BRCA2 mutation elected to undergo prophylactic salpingo-oophorectomy between 35 and 40 years of age 19, 32 Vthus before menopause. Prophylactic salpingo-oophorectomy, especially in premenopausal women, may negatively impact several aspects of quality of life and health. 33, 34 Symptoms of surgical menopause are attributed to decreased levels of circulating hormones produced by the ovaries; a dramatically rapid decline in estrogen and androgen levels after bilateral oophorectomy in premenopausal women has been reported. 35, 36 According to several studies, surgical menopause in younger women can result in severe hot flashes, vaginal dryness, sexual dysfunction, sleep disturbances, and cognitive changes that may significantly affect quality of life. 37 More impressively, an association between bilateral oophorectomy and increased risk of cardiovascular disease has been suggested in a number of observational studies. 20 The Nurses' Health Study reported on the relationship between menopause (natural and surgical) and the subsequent risk of coronary heart disease in 121,700 women aged between 30 and 55 years 38 and found that bilateral oophorectomy could be a risk factor for coronary heart disease in the general population. 38<40 In these studies, the risk for cardiovascular disease was definitely more pronounced for women who underwent artificial menopause than for women who underwent natural menopause, advocating an increase in risk with bilateral oophorectomy before the age of 50 years (relative risk [RR], 4.55; 95% CI, 2.56-8.10). 40 Finally, studies in the last decades 41, 42 confirmed the benefits of prophylactic salpingo-oophorectomy on mortality reduction, probably attributable to the prevention of breast and ovarian cancers. Conversely, the beneficial effect seen in mutation carriers has not been confirmed in the general population, 22, 34 and some data need to be underlined. In particular, the Mayo Clinic Cohort of Oophorectomy and Aging analyzed mortality associated with bilateral oophorectomy by comparing 1,091 women who underwent bilateral oophorectomy, 1,274 who underwent unilateral oophorectomy, and 2,383 who did not undergo oophorectomy (referent group). They found that women who underwent bilateral oophorectomy did not have an increased risk of death when compared with women who did not undergo oophorectomy. 34 Nevertheless, mortality was significantly higher in women who had had prophylactic bilateral oophorectomy before the age of 45 years compared with referent women (hazard ratio [HR], 1.67; 95% CI, 1.16-2.40), and this increased mortality was seen mainly in women who had not received estrogen up to the age of 45 years. 34 Therefore, the health benefits of salpingo-oophorectomy (cancer prevention)Vwhen plannedVshould outweigh the costs of the procedure in relation to quality of life and long-term health.
RRSO AND HT: IMPACT ON QUALITY OF LIFE
AND SAFETY CONCERNS Non-HTs, such as serotonin receptor inhibitors (venlafaxine and paroxetine) and >2 adrenergic agonists (clonidine), are reasonable options for the treatment of vasomotor symptoms after surgical menopause but are not as effective as HT 17 and have toxic effects leading to premature treatment discontinuation. 43<45 Similarly, complementary and alternative approaches, such as phytoestrogens, are undergoing investigation; however, to date, there is little evidence to support their use for control of menopausal symptoms. 46 Therefore, HT remains the gold standard for the treatment of menopausal disorders; several authors advocate the use of HT as a viable treatment option for premenopausal BRCA carriers without prior breast cancer after prophylactic bilateral salpingo-oophorectomy.
After previous controversial results on the role of HT in quality of life among oophorectomized BRCA carriers, 47<49 more trials have definitively confirmed the advantage of HT for treating menopausal discomfort due to RRSO (Table 1) . Madalinska et al 50 conducted an observational study on 164 premenopausal women at high risk for hereditary ovarian cancer who had undergone bilateral salpingo-oophorectomy, 47% of whom were current HT users (estrogen-progestogen therapy [EPT] ). An 18-item functional assessment of cancer therapy and endocrine symptoms was used to evaluate menopausal symptoms. EPT users reported significantly fewer vasomotor symptoms (P G 0.05) and comparable levels of sexual functioning than nonusers.
Madalinska et al 50 conducted the last published study on the impact of HT (ET or EPT) after prophylactic salpingooophorectomy on menopausal symptoms and sexual function in BRCA carriers. In this prospective study, 114 women with BRCA1/2 mutations were invited to complete the Menopause-Specific Quality of Life Intervention questionnaires before surgical operation and 1 year after surgical operation. Seventyfive women (66%) were premenopausal at the time of surgical operation, and 29 (38.7%) of them reported taking HT at the time of follow-up. Thirty-nine women were postmenopausal before surgical operation, and four (10.2%) of them were taking HT. Furthermore, 41% (47 of 114 women) have had a previous diagnosis of breast cancer. Women who were premenopausal at the time of surgical operation experienced a worsening of hot flashes, night sweats, and sweating, and a decline in sexual function. Interestingly, women who took HT experienced fewer hot flashes than women who did not take HT after surgical operation; on average, the hot flashes were less severe. Women who were taking HT experienced significantly less Favoring HT users (P = 0.015); sexual discomfort decreased in HT users
Favoring HT users (P = 0.0003); hot flashes decreased in HT users vaginal dryness and sexual discomfort than women who did not take HT after surgical operation. Finally, HT did not prevent sexual pleasure decline after surgical operation. Despite the symptoms related to surgical menopause, satisfaction with the decision to undergo prophylactic salpingo-oophorectomy was high; remarkably, satisfaction was negatively correlated with sexual discomfort, but not with sexual pleasure. 37 The positive results of these studies led to the presumption that HT may significantly improve quality of life in women with menopausal symptoms; however, the abovementioned trials also underline the lack of homogeneity of these studies, especially regarding some important characteristics of the women involved, such as menopause status, age at RRSO, and ethnicity. Similarly, several methodological aspects, including administered questionnaires, quality-of-life scores, and type of HT used, are extremely heterogeneous, delaying the generalization of the findings.
Nevertheless, although HT may significantly improve quality of life in women with menopausal symptoms, it is still fervently debated whether HT is safe for women after gynecologic cancer treatment 51 or for women with an increased risk of breast and ovarian cancers. Safety concerns with HT have been raised after the results of some trials. 52, 53 These studies advised of a possible increase in breast cancer risk among HT users. In the WHI randomized trial, 52 a statistically significant increase in breast cancer risk was observed with the use of combined therapy (EPT; HR, 1.3; 95% CI, 1.0-1.6), but not with estrogen alone, in hysterectomized women (HR, 0.8; 95% CI, 0.6-1.0). 54 Conversely, the observational Million Women Study (MWS) found that HT users at recruitment were more likely to develop (RR, 1.66; 95% CI, 1.58-1.75) and die of (RR, 1.22; 95% CI, 1.00-1.48) breast cancer than nonusers, independent of the use of both estrogen and progesterone (RR, 2.00; 95% CI, 1.88-2.12) or estrogen alone (RR, 1.30; 95% CI, 1.21-1.40). The MWS also found an increased risk of ovarian cancer among current HT users, who were more likely to develop and die of ovarian cancer than nonusers. 53 Nevertheless, both studies had significant limitations.
The MWS data are not randomized and therefore subject to responder bias and recall, and the data on HT use were only collected at the start of the study (ie, any change or discontinuation of HT was not documented). Regarding the WHI randomized trial, a high proportion of the women were obese and had a mean age of 63 years. Finally, participants in both studies often were postmenopausal: in the MWS, women were aged 50 to 64 years at recruitment (mean, 56 y), and in the WHI randomized trial, they were aged 50 to 79 years (mean, 63 y).
All these biases justify the increasing number of studies investigating the role of HT in the general population, especially in women with gynecologic cancers or who had surgical menopause to prevent breast and ovarian cancers ( Table 2) .
Armstrong et al 54 used a Markov decision analytic model to assess the expected outcomes of prophylactic oophorectomy with or without HT (up to the age of 50 y or for life) in a cohort of women with BRCA1/2 mutations. In this analysis, prophylactic oophorectomy seemed to increase life expectancy in women with BRCA1/2 mutations, irrespective of whether HT (unspecified type) was used after oophorectomy. This increment ranged from 3.34 to 4.65 years, depending on age at oophorectomy. The use of HT after bilateral oophorectomy was associated with relatively small changes in life expectancy (from +0.17 to j0.34 y) when HT was stopped at the age of 50 y; however, larger decrements in life expectancy were observed when HT was continued for life (j0.79 to j1.09 y). HT was associated with a gain in life expectancy of between 0.39 and 0.79 years for mutation carriers undergoing both prophylactic mastectomy and oophorectomy. Therefore, they concluded that women should decide about short-term HT after oophorectomy based largely on quality-of-life issues rather than on life expectancy and, if using HT, should consider discontinuing treatment at the time of expected natural menopause, approximately at 50 years. Later on, Rebbeck et al 55 performed a large prospective cohort study in 462 women (mean age, 42.7 y) with disease-associated germline BRCA1/2 mutations to evaluate breast cancer risk after RRSO with and without HT (ET or EPT). Consistent with the abovementioned report, after a median follow-up of 3.6 years, they found that RRSO was significantly associated with breast cancer risk reduction (HR, 0.40; 95% CI, 0.18-0.92) and that HT of any type (EPT or ET) after RRSO did not significantly alter the reduction in breast cancer risk associated with RRSO (HR, 0.37; 95% CI, 0.14-0.96).
Positive results were also found in the matched case-control study performed by Eisen et al 56 on 472 postmenopausal women with BRCA1 mutation, which was conducted to examine whether the use of HT (ET or EPT) was associated with a subsequent risk of breast cancer. The adjusted odds ratio for breast cancer associated with ever use of HT, when compared with never use of HT, was 0.58 (95% CI, 0.35-0.96; P = 0.03). An analysis based on HT type showed an inverse association between breast cancer risk and the use of estrogen alone (odds Women with breast cancer, 3/33; 9.09% HT, hormone therapy; RRSO, risk-reducing salpingo-oophorectomy; E 2 , estrogen therapy; PG + E 2 , progesterone + estrogen combined therapy; HR, hazard ratio; OR, odds ratio. ratio, 0.51; 95% CI, 0.27-0.98; P = 0.04). Neither the use of estrogen alone nor the use of estrogen combined with progesterone was associated with an increase in breast cancer risk among BRCA1 mutation carriers. However, in this study, different from that expected, BRCA-associated breast cancers arising after oophorectomy and HT use were more often estrogen receptorY negative (23% vs 12%), confirming that most breast cancers that develop in BRCA1 carriers are estrogen/progesterone receptorY negative, 21 providing further rationale for considering ET.
Finally, Gabriel et al 57 retrospectively investigated 73 female BRCA1/2 mutation carriers who underwent RRSO and collected information regarding whether total abdominal hysterectomy was performed in addition to RRSO, the type of HT, and the subsequent diagnosis of breast cancer. Of the 33 HT users included in the study, 17 (17 of 33; 52%) were using estrogen alone and 14 (14 of 33; 42%) were using combined HT. Interestingly, they found that of the 33 (9%) women who used HT, three subsequently developed breast cancer, compared with 9 (31%) of 29 women who did not use HT. Furthermore, all HT users who developed breast cancer received estrogen-only therapy, whereas none of the women who used combined HT or had an Bunknown[ HT type developed breast cancer.
The exciting results of these aforementioned and wellconducted studies should be balanced on the fact that none of these trials were randomized controlled trials but were mainly case-control or prospective cohort studies; therefore, the number of enrolled women who underwent RRSO followed by HT is not adequately large.
On the other hand, extreme caution should be taken when considering HT for BRCA mutation carriers with a personal history of breast cancers. Evidence indicates that combined estrogen-progestin regimens are associated with new breast cancers in women with a history of breast cancer. The HABITS trial 58 was stopped prematurely in 2003 after an unacceptably high incidence of recurrent, contralateral, and metastatic disease was noted in women with a history of treated stage II breast cancer who were receiving HT.
CONCLUSIONS
Prophylactic oophorectomy is the mainstay of ovarian cancer prevention in women with a BRCA1 or BRCA2 mutation; therefore, understanding and management of the longterm impact of the surgical operation is mandatory. Prophylactic surgical menopause seems to impair quality of life, especially vasomotor symptoms and sexual functioning, in women. HT could be a valid approach to mitigating most of these symptoms. Despite the limitations of retrospective and prospective observational studies and the need for more randomized trials, current evidence suggests that short-term HT does not seem to have an adverse effect on oncologic outcomes in BRCA1 and BRCA2 mutation carriers without a personal history of breast cancer. Much effort has been exerted to elucidate the feasibility and safety of HT in oophorectomized BRCA mutation carriers. Nevertheless, well-designed randomized controlled trials are still lacking and should be preferably dedicated to premenopausal women who undergo RRSO with or without hysterectomy not only to investigate the safety of HT in this setting but also to propose the drugs of choice and the duration of this therapeutic option to well-categorized women.
Finally, women who decide to undergo prophylactic salpingooophorectomy should be carefully counseled in a multidisciplinary setting, including geneticists, gynecologic oncologists/ gynecologists, psychologists, and additional specialists, for the management of vasomotor symptoms, sexual health, bone health, and possibly cardiac health (Table 3) . Excise the fallopian tubes because of a theoretical risk of fallopian tube cancer. 25 Reduce the risk of endometrial pathology in women on tamoxifen therapy. 25 Simplify HT so that estrogen-only therapy may be considered. 25 Implications after RRSO RRSO, especially when performed before natural menopause, may negatively impact on several aspects of quality of life and health. 33, 34 Women who undergo bilateral oophorectomy before the age of 45 years have an increased risk of death. 34 
RRSO and HT: impact on quality of life and safety concerns
Non-HTs are reasonable options for the treatment of vasomotor symptoms after surgical menopause but are not as effective as HT. Short-term HT does not seem to have an adverse effect on oncologic outcomes in BRCA1 and BRCA2 mutation carriers without a personal history of breast cancer. RRSO, risk-reducing salpingo-oophorectomy; HT, hormone therapy.
